Sermorelin — reference
GHRH analog, historically FDA-approved (Geref, now discontinued) and still compounded/prescribed off-label for GH support.
Regulatory status
Not FDA-Approved. No longer marketed as an FDA-approved product; typically obtained via a compounding pharmacy prescription.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~10–20 minutes. GHRH(1-29) fragment; rapidly degraded, consistent with native GHRH's own short half-life.
This figure is tagged PK study in our evidence system. This figure comes from a published pharmacokinetic study rather than a label or registration trial. Sample sizes in such studies are often small and figures vary between them, so treat the number as a range rather than a constant. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Sermorelin FDA-approved?
What is the half-life of Sermorelin?
How reliable is that half-life figure?
What cautions are associated with Sermorelin?
Does Peptide Plug publish dosing for Sermorelin?
Does Peptide Plug sell Sermorelin?
Related tools
Free, no account required.